伊布替尼重编程慢性淋巴细胞白血病细胞中的糖皮质激素受体
研究慢性淋巴细胞白血病(CLL)细胞中糖皮质激素受体(GR)磷酸化及特征基因,发现CLL细胞存在内在糖皮质激素抵抗,与GR Ser211活化位点和Ser226抑制位点异常磷酸化相关。伊布替尼可增加循环CLL细胞中GR特征基因GILZ转录及GR(pS211)/GR(pS226)比值,并增强对地塞米松的溶解敏感性;在模拟假滤泡微环境条件下,加用鲁索替尼可增加GILZ转录、GR(S211)/GR(S226)比值及地塞米松介导的杀伤。
要点
- CLL细胞对糖皮质激素的内在抵抗与GR Ser211和Ser226位点异常磷酸化相关。
- 伊布替尼可提高循环CLL细胞中GILZ转录及GR(pS211)/GR(pS226)比值,增强地塞米松溶解敏感性。
- 在假滤泡条件下,加用鲁索替尼可增加GILZ转录、GR(S211)/GR(S226)比值及地塞米松介导的杀伤。
核心结论
- CLL细胞的内在糖皮质激素抵抗是其特征,伊布替尼可能通过非经典途径激活GR来增强糖皮质激素的治疗活性。
研究设计与样本
- 研究在慢性淋巴细胞白血病(CLL)细胞中检测糖皮质激素受体(GR)磷酸化及特征基因,并开展体外实验及一项临床试验(NCT02912754)。
主要发现
- 与正常B细胞和T细胞不同,CLL细胞中糖皮质激素调节基因的转录无节律性,且地塞米松不能抑制CLL细胞对Toll样受体(TLR)的应答。
- 这种内在糖皮质激素抵抗与GR在活化位点Ser211和抑制位点Ser226的异常磷酸化相关。
- 伊布替尼增加循环CLL细胞中GR特征基因GILZ的转录以及GR(pS211)/GR(pS226)比值,并增强对地塞米松的溶解敏感性,体外实验中米非司酮不能逆转这些效应。
- 在模拟假滤泡微环境、用IL2和TLR7/8激动剂激活的循环CLL细胞中,伊布替尼不能改善GR应答。
- 在体外假滤泡条件下及一项临床试验(NCT02912754)中,加用Janus激酶抑制剂鲁索替尼阻断伊布替尼不敏感信号,可增加GILZ转录,并在体外患者样本中增加GR(S211)/GR(S226)比值及地塞米松介导的杀伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucocorticoid (GC) receptor (GR) phosphorylation and signature genes were studied in chronic lymphocytic leukemia (CLL) cells to help place GCs within modern treatment algorithms. In contrast to normal B and T cells, transcription of GC-regulated genes was not rhythmic and the synthetic GC dexamethasone (DEX) could not inhibit toll-like receptor (TLR)-responses in CLL cells. This intrinsic GC-resistance was associated with aberrant GR-phosphorylation on activating Ser211 and inhibitory Ser226 sites. Ibrutinib increased transcription of the GR-signature gene GILZ in circulating CLL cells along with GR(pS211)/GR(pS226) ratios and lytic sensitivity to DEX that were not reversed by the competitive antagonist mifepristone in vitro. However, ibrutinib could not improve GR-responses in circulating CLL cells activated with IL2 and TLR7/8 agonists to mimic conditions in pseudofollicle microenvironments. Addition of the janus kinase inhibitor ruxolitinib to block ibrutinib-insensitive signals increased GILZ transcription in pseudofollicle conditions in vitro and in a clinical trial (NCT02912754), and also increased GR(S211)/GR(S226) ratios and DEX-mediated killing in patient samples in vitro. These observations suggest that intrinsic resistance to endogenous GCs is characteristic of CLL cells and ibrutinib may help increase the therapeutic activity of GCs by non-canonical activation of GR.
引用
- Shi Y, Wang G, Muhowski EM, et al. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. Leukemia. 2019. PMID: 30696950. doi:10.1038/s41375-019-0381-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。